<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608179</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #020690</org_study_id>
    <nct_id>NCT00608179</nct_id>
  </id_info>
  <brief_title>Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia</brief_title>
  <official_title>Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at two FDA approved medications that improve how the pancreas works in
      patients with Type 2 Diabetes. In order to understand how these medications work in patients
      with diabetes we must first measure the normal response in healthy volunteers without
      diabetes. We will be looking at the body's normal physiological response to low blood sugar
      and whether this will be modified by these medicationsThe hypothesis would be that
      glimepiride induced insulin secretion will be inhibited by hypoglycemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with type 2 diabetes, sulfonylurea drugs are a mainstay for effective glucose
      control. These agents produce their hypoglycemic effects via stimulation of endogenous
      insulin secretion. Oversecretion of insulin, per se, or a continued relative increase of the
      hormone even when plasma glucose is normal will result in hypoglycemia. This latter situation
      commonly occurs if a patient decides to omit, delay, or reduce the size of a meal. An
      important defense against hypoglycemia in the above situations is glucose dependent
      regulation of insulin secretion. In other words, a low ambient glucose concentration could
      regulate the magnitude of the amount of insulin released in response to a sulfonylurea. Thus
      during hypoglycemic conditions, the sulfonylurea would result in little or no insulin
      secretion, whereas its effects during hyperglycemia would be amplified. Glimepiride and
      glyburide are both second-generation sulfonlyurea drugs used commonly for treatment of type 2
      diabetes. This study will compare the two and ask the following question:

      Is Glimepiride insulin secretion dependent upon glucose concentration in-vivo?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>catecholamines</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control-euglycemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control-hypoglycemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Amaryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glyburide</intervention_name>
    <description>Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Dia-Beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>glucose clamp</intervention_name>
    <description>Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>glucose clamp</intervention_name>
    <description>hypoglycemic glucose clamp procedure -120 minutes</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects aged 30-60

          -  Body Mass Index 21-30 kg/m2

          -  All potential volunteers will have routine blood test to screen for hepatic, renal,
             and hematological abnormalities

          -  EKG treadmill stress test for volunteers over 40 years of age.

          -  Female volunteers of childbearing potential will undergo HCG pregnancy test.

        Exclusion Criteria:

          -  Prior or current history of poor health

          -  Abnormal results following screening tests

          -  Pregnancy

          -  History of allergy to sulfonylurea or related drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N. Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Steve Davis</investigator_full_name>
    <investigator_title>Department Chair</investigator_title>
  </responsible_party>
  <keyword>epinephrine</keyword>
  <keyword>glucose clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

